Female, 32 years of age, well aware of the fact she had type 1 diabetes, was suicidal, who reported she chose to stop taking her insulin a few days earlier. Was taken to the police station on a warrant (unknown reason), who took her to the ED due to her report of suicidal ideation. She was found to be hyperglycemic at that time, but did not say she had type 1. Acetone was negative. Given 5 units regular insulin and sent back with police. She then started complaining of not feeling well, taken back to ED, no treatment and sent back with police. The next morning, complained of nausea, vomiting, and abdominal pain.

In part 5 of this Exclusive Interview, Kimberly Ward explains how the Accu-Chek system helps the patient to manage their blood glucose.

In this week's Homerun Slides, precision medicine - matching the right drug to the right patient.

Beta-Cell response to intravenous glucose: Although in normal living conditions beta cells are stimulated by hyperglycemia that follows glucose ingestion, the study of the response to intravenous glucose is of fundamental importance for understanding the physiology of beta cells. Several tests have been developed for this purpose and this section describes the most relevant and the characteristics of insulin secretion that they reveal.

Last week the FDA announced that they were going to approve 6 different manufacturers for the production of rosuvastatin calcium, the generic version of Crestor. It appears that the FDA has decided that if they let more companies produce the generic, the price may not be as high to start …

Is once-daily delayed release metformin better than the other forms of metformin?

We have studies that show exercise for older women is very beneficial; new study shows benefits for the young.

Does insulin cause more deaths and cardiovascular outcomes than GLP-1 agonist receptors?

In part 3 of this exclusive interview, Dr. Eckel discusses the new PCSK9 Inhibitors and their LDL-lowering effects, and why they are beneficial for statin-intolerant patients.

In part 2 of this exclusive interview, Dr. Eckel discusses the new diabetes drugs that offer treatment benefits beyond glucose control, and why 1 + 1 + 1 + 1 may add up to more than 4 when impacting multiple risks.